Big Pharma

The race for a coronavirus vaccine proves big pharma isn't fit for purpose


18 March 2020

As the spread of coronavirus continues unabated, the response of the pharmaceutical industry is being thrust into the spotlight. For years, major public health crises have exposed the fundamental conflict between profit and public health in our pharmaceutical system.

Health campaigners have called for the government to make major changes to the way medicines are researched and developed, after new analysis of the cost of leading cancer drugs to the NHS showed that £458 million was spent in 2017/18 on paying pharmaceutical companies for medicines developed with public funding.

Are Big Pharma holding patients to ransom to boost their profits?


23 June 2017

The NHS has been forced into yet another secretive deal with a big pharmaceutical company to ensure access for cancer patients to the newest medicines. But while access to new drugs is obviously good news for cancer patients, the deal itself paints a bleak picture for the future of our NHS.

Subscribe to RSS - Big Pharma

Latest posts

The race for a coronavirus vaccine proves big pharma isn't fit for purpose


18 March 2020

As the spread of coronavirus continues unabated, the response of the pharmaceutical industry is being thrust into the spotlight. For years, major public health crises have exposed the fundamental conflict between profit and public health in our pharmaceutical system.

Are Big Pharma holding patients to ransom to boost their profits?


23 June 2017

The NHS has been forced into yet another secretive deal with a big pharmaceutical company to ensure access for cancer patients to the newest medicines. But while access to new drugs is obviously good news for cancer patients, the deal itself paints a bleak picture for the future of our NHS.

Resources

There are currently no published resources available.

Latest news

Health campaigners have called for the government to make major changes to the way medicines are researched and developed, after new analysis of the cost of leading cancer drugs to the NHS showed that £458 million was spent in 2017/18 on paying pharmaceutical companies for medicines developed with public funding.